Zhi Chen

Associate Professor at University of Oulu

University of Oulu
Country flagFinland

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Zhi Chen is an Associate Professor at the University of Oulu, Finland. His research focuses on immunology and cancer biology, with recent articles exploring the role of Ku70 in Treg function in lung adenocarcinoma, genetic influences on interferon gamma deficiency in ocular toxoplasmosis, and plasma proteomics related to COVID-19 and colorectal cancer. Dr. Chen's work contributes to understanding immune signatures and biomarkers in various diseases.

Positions (1)

Publisher
source

Zhi Chen

University Name
.

University of Oulu

The University of Oulu is recruiting a Postdoctoral Researcher in Immunological Mechanisms of Inflammation and Tumorigenesis at the Faculty of Biochemistry and Molecular Medicine in Oulu, Finland. The position is part of a multidisciplinary and international research environment focused on biochemistry, molecular medicine, and disease-related cellular regulation. The project investigates the immunological mechanisms of inflammation and tumorigenesis , with a particular emphasis on the role of helper T lymphocytes . Research will combine in vitro assays and in vivo disease models , alongside cutting-edge systems biology methods such as RNA-seq, ChIP-seq, proteomics, and single-cell omics . The exact project direction will be agreed upon according to the selected candidate’s qualifications, interests, and expertise. The post is suited to candidates with expertise in immunology and strong experience in cell biology or molecular biology . Applicants must hold a recent PhD in life sciences , completed by the closing date and obtained no more than 10 years ago. Experience with animal work is preferred. The university also values publication experience, ability to attract supplementary funding, teaching experience, bioinformatics and IT skills, and strong communication and teamwork. As part of the faculty, the successful researcher may also supervise BSc, MSc, and PhD students , contribute to teaching, and participate in research funding applications. The role is full time and fixed-term for 16 months , with a starting gross salary of approximately €3,600–€4,200 per month before taxes, plus possible performance-based pay. The position includes a trial period of 6 months. Applications must be submitted through the university recruitment system by 14 August 2026 . Materials should include a cover letter, CV, publication list, certificates/diplomas, and contact information for two referees. The application must be written in English. For questions about the post, contact Dr Zhi Chen, Associate Professor at [email protected] .

2 months ago

Articles (8)

Despite great scientific efforts, deep understanding of coronavirus-19 disease (COVID-19) immunopathology and clinical biomarkers remains a challenge. Pre-existing comorbidities increase the mortality rate and aggravate the exacerbated immune response against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, which can result in more severe symptoms as well as long-COVID and post-COVID complications. In this study, we applied proteomics analysis of plasma samples from 28 patients with SARS-CoV-2, with and without pre-existing comorbidities, as well as their corresponding controls to determine the systemic protein changes caused by the SARS-CoV-2 infection. As a result, the protein signature shared amongst COVID-19 patients with comorbidities was revealed to be characterized by alterations in the coagulation and complement pathways, acute-phase response proteins, tissue damage and remodeling, as well as cholesterol metabolism. These altered proteins may play a relevant role in COVID-19 pathophysiology. Moreover, several novel potential biomarkers for early diagnosis of the SARS-CoV-2 infection were detected, such as increased levels of keratin K22E, extracellular matrix protein-1 (ECM1), and acute-phase response protein α-2-antiplasmin (A2AP). Importantly, elevated A2AP may contribute to persistent clotting complications associated with the long-COVID syndrome in patients with comorbidities. This study provides new insights into COVID-19 pathogenesis and proposes novel potential biomarkers for early diagnosis that could be facilitated for clinical application by further validation studies.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (2)

Diana M. Toivola

Åbo Akademi University

FINLAND
View details

Daniela Mennerich

University of Oulu

FINLAND
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.